Guardian Investment Management Has $1.51 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Guardian Investment Management lowered its holdings in Pfizer Inc. (NYSE:PFE) by 11.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 52,400 shares of the biopharmaceutical company’s stock after selling 7,005 shares during the quarter. Pfizer accounts for about 1.2% of Guardian Investment Management’s investment portfolio, making the stock its 25th largest position. Guardian Investment Management’s holdings in Pfizer were worth $1,509,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Worth Asset Management LLC acquired a new position in Pfizer in the first quarter valued at about $29,000. Briaud Financial Planning Inc acquired a new position in Pfizer in the third quarter valued at about $30,000. GoalVest Advisory LLC grew its stake in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the period. Mizuho Securities Co. Ltd. acquired a new position in Pfizer in the third quarter valued at about $34,000. Finally, VisionPoint Advisory Group LLC grew its stake in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.4 %

PFE traded down $0.09 on Thursday, hitting $25.33. 25,992,584 shares of the company were exchanged, compared to its average volume of 42,343,496. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock’s fifty day moving average is $27.19 and its 200-day moving average is $28.76. The company has a market cap of $143.43 billion, a PE ratio of 70.25, a PEG ratio of 1.16 and a beta of 0.61. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.56.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.14 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PFE. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.